Financial Comparison: SAB Biotherapeutics (NASDAQ:SABS) & Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ:VKTX) and SAB Biotherapeutics (NASDAQ:SABS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Risk & Volatility

Viking Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Earnings and Valuation

This table compares Viking Therapeutics and SAB Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$109.96 million	($2.12)	-13.82
SAB Biotherapeutics	$1.32 million	152.57	-$34.10 million	($3.09)	-1.37

SAB Biotherapeutics has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Viking Therapeutics and SAB Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-29.35%	-28.41%
SAB Biotherapeutics	N/A	33.39%	25.33%

Insider and Institutional Ownership

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Viking Therapeutics and SAB Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	2	2	7	3	2.79
SAB Biotherapeutics	1	0	4	1	2.83

Viking Therapeutics presently has a consensus price target of $89.36, suggesting a potential upside of 205.00%. SAB Biotherapeutics has a consensus price target of $10.00, suggesting a potential upside of 136.41%. Given Viking Therapeutics’ higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than SAB Biotherapeutics.

Summary

SAB Biotherapeutics beats Viking Therapeutics on 7 of the 13 factors compared between the two stocks.

About Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.